Torrent Pharmaceuticals Limited
Quick Take
- • Trading at 77.6× trailing earnings (52.0× forward)
- • Strong ROE at 23.1%
- • Leveraged balance sheet (D/E 0.85)
- • Modest dividend yield of 0.78%
- • Operating margin 21.8% · Net margin 13.9%
- • Profit growth -8.20% YoY · Beta 0.14
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 4,835 | +17.13% | +54.57% |
| Operating Profit | 1,631 | +28.12% | +63.92% |
| Net Profit | 566 | +45.50% | +3.28% |
| EPS (₹) | 14.87 | +29.19% | -8.15% |
About the company
From latest AR & concallTorrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
